Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Public ClinicalTrials.gov record NCT03548987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During run-in Period
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what a participant can do to lose weight. The participant will get semaglutide for the first 20 weeks. Then the participant will get either semaglutide or "dummy" medicine - which treatment the participant gets after the 20 weeks is decided by chance. The participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years.
Study identification
- NCT ID
- NCT03548987
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 902 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 4, 2018 (Actual)
- Primary completion
- Feb 22, 2020 (Actual)
- Completion
- Mar 20, 2020 (Actual)
- Last update posted
- Jan 19, 2022
2018 – 2020
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Anniston | Alabama | 36207 | — |
| Novo Nordisk Investigational Site | Fresno | California | 93720 | — |
| Novo Nordisk Investigational Site | San Diego | California | 92108 | — |
| Novo Nordisk Investigational Site | Alpharetta | Georgia | 30022 | — |
| Novo Nordisk Investigational Site | Roswell | Georgia | 30076 | — |
| Novo Nordisk Investigational Site | Suwanee | Georgia | 30024 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40213 | — |
| Novo Nordisk Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| Novo Nordisk Investigational Site | Elkridge | Maryland | 21075-6437 | — |
| Novo Nordisk Investigational Site | Buckley | Michigan | 49620 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68198-3020 | — |
| Novo Nordisk Investigational Site | New York | New York | 10016 | — |
| Novo Nordisk Investigational Site | Greensboro | North Carolina | 27408 | — |
| Novo Nordisk Investigational Site | Greenville | North Carolina | 27834 | — |
| Novo Nordisk Investigational Site | Raleigh | North Carolina | 27612 | — |
| Novo Nordisk Investigational Site | Salisbury | North Carolina | 28144 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45242 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45406 | — |
| Novo Nordisk Investigational Site | Bristol | Tennessee | 37620-7352 | — |
| Novo Nordisk Investigational Site | Bristol | Tennessee | 37620 | — |
| Novo Nordisk Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78731 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75226 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75231 | — |
| Novo Nordisk Investigational Site | Arlington | Virginia | 22206 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23226 | — |
| Novo Nordisk Investigational Site | Wenatchee | Washington | 98801-2028 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03548987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2022 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03548987 live on ClinicalTrials.gov.